WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management will present at upcoming virtual investor conferences.
Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, will participate in fireside chats at the following:
- Stifel 2020 Virtual Healthcare Conference; Monday, November 16, 2020 at 10:00 a.m. ET
- Jefferies Virtual London Healthcare Conference; Thursday, November 19, 2020 at 7:55 a.m. ET
- Piper Sandler 32nd Annual Virtual Healthcare Conference; pre-recorded and expected to be available Monday, November 23, 2020
Webcasts and recordings will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/investors-and-media and accessible for 90 days following each presentation.
About Dyne Therapeutics
Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. The Company utilizes its proprietary FORCE™ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit www.dyne-tx.com, and follow us on Twitter, LinkedIn and Facebook.
Contact:
Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203